Pancreatic Cancer
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
One of the deadliest major cancers, often diagnosed late; most cases are driven by KRAS mutations.
If Pancreatic Cancer is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer · Cancer Cell · 2026-09-18
- Propionyl-CoA catabolism is a metabolic gatekeeper for fatty acid oxidation in pancreatic cancer. · Oncogene · 2026-09-11
- ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. · iScience · 2026-09-08
- The Liquid Biopsy That Found Pancreatic Cancer Early Has a Bigger Regulatory Problem Than Its Science · The Clinical Trial Vanguard · 2026-09-21 · usually covers Auto
- Liquid Biopsy Shows Potential to Detect Pancreatic Cancer Before It Turns Invasive · Inside Precision Medicine · 2026-09-17 · usually covers Precision Medicine
- ApoA2 isoforms as blood-based biomarkers reflecting pancreatic exocrine dysfunction for risk stratification and perioperative management of pancreatic cancer · Frontiers Precision Oncology · 2026-09-17 · usually covers Precision Medicine
What the reporting says
Across 111 tracked stories from 53 outlets, reporting on Pancreatic Cancer most often describes regulatory approvals (20), launches or releases (4), award (1), meetings or visits (1).
It shows up alongside KRAS (49), Pdac (18), Colorectal Cancer (17), Immunotherapy (13), Lung Cancer (13), Overall Survival (17), ctDNA (10), FDA (33).
Two steps out: KRAS Mutant (through KRAS, 45 shared stories on the weaker link); Egfr (through KRAS, 37 shared stories on the weaker link); AI (through FDA, 33 shared stories on the weaker link); Cder (through FDA, 33 shared stories on the weaker link).
Tracked since Jan 1, with coverage on 61 separate days — concentrated in Oncology and Pubmed Targeted.